SAN FRANCISCO, Oct. 18, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of $175.5 million in aggregate gross proceeds, or 13,000,000 shares of its common stock at a public offering price of $13.50 per share. In connection with this offering, Nektar has also granted to the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of common stock at the offering price.
J.P. Morgan is acting as lead book-running manager in the offering. Jefferies and Piper Jaffray are acting as book-running managers. William Blair is acting as lead manager for the offering, and Brean Capital, BTIG, Janney Montgomery Scott, Ladenburg Thalmann and ROTH Capital Partners are acting as co-managers for the offering.
Nektar intends to use the net proceeds from this offering for general corporate purposes including research and development funding and working capital.
The securities described above are being offered by Nektar pursuant to an effective shelf registration statement, including a prospectus supplement and accompanying prospectus, copies of which may be obtained from the offices of J.P. Morgan Securities LLC, attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, NY 11717, or telephone: 866-803-9204.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Jennifer Ruddock 415-482-5585
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-prices-public-offering-of-shares-of-common-stock-300347360.html
SOURCE Nektar Therapeutics